Drug Profile

Galeterone companion diagnostic

Alternative Names: AR-V7 companion diagnostic

Latest Information Update: 07 Jan 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Tokai Pharmaceuticals
Developer Novus Therapeutics
Class Diagnostic agents
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Discontinued Prostate cancer

Most Recent Events

04 Jan 2021 Novus Therapeutics is now called Eledon Pharmaceuticals
10 Dec 2018 Discontinued - Phase-III for Prostate cancer (Diagnosis) in USA before December 2018 (Novus Therapeutics website, December 2018)
31 Mar 2017 QIAGEN in-licenses AR-V7 biomarker from Johns Hopkins University

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com